Lecanemab Reduces Alzheimer's Side Effects
This is a news story, published by ScienceDaily, that relates primarily to Lecanemab news.
Lecanemab news
For more Lecanemab news, you can click here:
more Lecanemab newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsScienceDaily news
For more news from ScienceDaily, you can click here:
more news from ScienceDailyAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
lecanemab infusions. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest early symptomatic Alzheimer news, mild Alzheimer news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
lecanemab treatmentScienceDaily
•Health
Health
Drug to slow Alzheimer's well tolerated outside of clinical trial setting

81% Informative
Drug to slow Alzheimer's well tolerated outside of clinical trial setting.
Side effects of lecanemab are manageable, study finds.
Only 1% of patients experienced severe side effects that required hospitalization.
Lecanemab is an antibody therapy that clears amyloid plaque proteins, extending independent living by 10 months .
"This report may help patients and providers better understand the risks of treatment, which are lower in patients with very mild symptoms of Alzheimer's." Story Source: Journal Reference: - Madeline Paczynski et al. Lecanemab Treatment in a Specialty Memory Clinic . JAMA Neurology , 2025 DOI: : 10.1001 /jamaneurol.2025.1232 Cite This Page:.
VR Score
92
Informative language
98
Neutral language
61
Article tone
formal
Language
English
Language complexity
70
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links